Health Care | Pharmaceuticals, Biotechnology & Life Sciences | Biotechnology
NASDAQ | Common Stock
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States.
The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer.
Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis.
EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 20, 24 | 0.00 Increased by +100.00% | -0.20 Increased by +100.00% |
| Nov 6, 23 | 0.00 Increased by +100.00% | -0.16 Increased by +100.00% |
| Aug 8, 23 | -0.15 Increased by +11.76% | -0.13 Decreased by -15.38% |
| May 8, 23 | -0.17 Decreased by -525.00% | -0.15 Decreased by -13.33% |
| Feb 23, 23 | -0.05 Decreased by -350.00% | -0.20 Increased by +75.00% |
| Nov 10, 22 | -0.18 Decreased by -20.00% | -0.20 Increased by +10.00% |
| Aug 11, 22 | -0.17 Increased by +63.12% | -0.19 Increased by +10.53% |
| May 13, 22 | 0.04 | -0.24 Increased by +116.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0.00 Decreased by N/A% | -82.63 M Decreased by -3.27% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -72.96 M Increased by +13.99% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -63.30 M Decreased by -127.18% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 135.10 M Increased by +10.94 K% | Increased by +N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -80.02 M Decreased by -100.59% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -84.82 M Decreased by -145.66% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | 232.86 M Increased by +968.34% | Increased by +N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | 1.22 M Increased by +100.69% | Increased by +N/A% Decreased by N/A% |